Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Victor Moyo, MD
Merrimack Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hopital Maissoneuve-Rosemont
Montreal, Quebec, Canada
- Mcgill University Jewish General Hospital
Montreal, Quebec, Canada
- Hopital Du Sacre-Coeur de Montreal
Montreal, Canada
- Cha St. Sacrement
Québec, Canada
- Onkogologisches Zentrum Munich
Munich, Germany
- Brustzentrum Hs Kliniken Wiesbaden
Wiesbaden, Germany
- Medico-Diagnostically Center of International Institution of Biological Systems N.A.S.M.
Berezina, Russia
- City Clinical Oncology Center
Saint Petersburg, Russia
- Leningrad Regional Oncology Center
Saint Petersburg, Russia
- Railway Clinical Hospital
Saint Petersburg, Russia
- Hospital Clinic (barcelona)
Barcelona, Spain
- Hospital Parc Tauli - Barcelona
Barcelona, Spain
- Vall D'Hebrón University Hospital
Barcelona, Spain
- Puerta de Hierro
Madrid, Spain
- Servicio de Oncología Médica / Hospital Universitario Gregorio Marañón
Madrid, Spain
- Achieve Clinical Research
Birmingham, Alabama, United States
- Achieve Clinical Research
Birmingham, Alabama, United States
- Arizona Center for Cancer Care
Glendale, Arizona, United States
- Pacific Cancer Medical Center
Anaheim, California, United States
- Beverly Hills Cancer Center
Beverly Hills, California, United States
- Wilshire Oncology Medical Group, Inc.
Corona, California, United States
- Southwest Cancer Center
Escondido, California, United States
- Hematology Oncology Associates, Inc.
Oakland, California, United States
- San Jose Medical Center
San Jose, California, United States
- Central Coast Medical Oncology Corporation
Santa Maria, California, United States
- Pasco-Pinellas Oncology
New Port Richey, Florida, United States
- Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- Horizon Oncology Center
Lafayette, Indiana, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Tennessee Cancer Specialists Oncology Clinical Trials Center for Biomedical Research
Knoxville, Tennessee, United States
- Tennessee Cancer Specialists, Oncology Clincial Trials Center for Biomedical Research
Knoxville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2010
- Primary completion
- 30 Jun 2014
- Completion
- 30 Sept 2014
- Last update posted
- 12 May 2016
- Registered enrollment
- 118
- Registry id
- NCT01151046
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.